West Pharmaceutical’s Q4 EPS Rises 12.1%, Revenue Beats; 2026 Sales Guided to $3.21–3.27B
West Pharmaceutical reported Q4 2025 adjusted EPS of $2.04, up 12.1% year over year and 11.5% above estimates, with revenue of $805 million, up 7.5% and 1.4% above forecasts. The company projects 2026 sales of $3.21–3.27 billion assuming a mid-2026 SmartDose sale to AbbVie and EPS of $7.85–8.20.
1. Q4 2025 Financial Results
West Pharmaceutical delivered adjusted Q4 2025 EPS of $2.04, a 12.1% year-over-year increase and 11.5% above estimates. GAAP EPS rose 2.2% to $1.82, while revenue reached $805 million, up 7.5% and 1.4% ahead of forecasts.
2. Segment Performance
The Proprietary Products segment generated $661.8 million in Q4, up 7.8% reported and 3.6% organically, driven by a 20.3% rise in high-value product components. Contract-Manufactured Products sales totaled $143.2 million, up 6.2% reported and 1.9% organic.
3. 2026 Guidance & SmartDose Sale
Q1 2026 sales are guided to $770–790 million, implying organic growth of 4.6–7.4%, and EPS of $1.65–1.70. Full-year revenue is projected at $3.21–3.27 billion with 5–7% organic net sales growth and adjusted EPS of $7.85–8.20, assuming the SmartDose 3.5 ml sale to AbbVie closes by mid-2026.